News und Analysen
Eli Lilly Stock: Oral Alternative Threatens Market Dominance
Eli Lilly faces a potential challenge to its dominant position in the lucrative GLP-1 market after Lexaria Bioscience Corp. reported breakthrough results with its oral DehydraTECH-tirzepatide
Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?
When it comes to clinical weight-loss treatments, GLP-1 therapies have taken the medical sector by storm. What started as off-label use by celebrities and social media influencers for cutting
Incyte Stock: Breakthrough Drug Shows Promise
Incyte Corporation is poised for significant market growth following positive results from two pivotal Phase 3 trials for Povorcitinib, its oral JAK1 inhibitor targeting Hidradenitis suppurativa
Microvision WA Aktie: Krise absehbar?
Die Aktie des Lidar-Technologiespezialisten Microvision verzeichnete am 17. März 2025 einen Kursanstieg um 2,34% auf 1,31 USD. Trotz dieser positiven Tagesentwicklung bleibt die langfristige Tendenz
Teleflex Aktie: Wettbewerbssituation unverändert
Die Teleflex Aktie verzeichnete am vergangenen Freitag einen moderaten Anstieg von 0,80% und erreichte damit einen Kurs von 126,50 EUR. Diese positive Entwicklung steht im Kontrast zur schwachen
Iridex Stock: Volatility Persists Amid Stable Fundamentals
Iridex Corporation (NASDAQ: IRIX) shares experienced significant fluctuations last week, with March 13, 2025 showing particularly volatile trading patterns. The Mountain View, California-based
ANI Stock: FDA Expands ILUVIEN Drug Approval
ANI Pharmaceuticals has achieved a significant milestone with the FDA's approval to expand its ILUVIEN medication for treating chronic non-infectious uveitis of the posterior segment (NIU-PS). This
Starke Verkaufszahlen für Cresemba® (Isavuconazol) in der Region Asien-Pazifik und China lösen Meilensteinzahlung an Basilea aus
Allschwil, 14. März 2025
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an
Eli Lilly Stock: Roche Deal Threatens Market Dominance
Eli Lilly's stock is facing pressure following a strategic partnership announcement between Swiss pharmaceutical giant Roche and Danish firm Zealand Pharma. The deal, valued at up to $5.3 billion
Johnson & Johnson Stock: Resilient Performance Amid Market Volatility
Healthcare giant Johnson & Johnson is demonstrating remarkable resilience in a volatile market environment. Currently trading at $165.68, the stock has established itself as a defensive asset
Merck Stock: Billion-Dollar Vaccine Facility Boosts US Presence
Merck, known internationally as MSD, has significantly strengthened its position in the American market with the opening of a new vaccine production facility in Durham, North Carolina. The
Celldex Therapeutics Aktie: Droht nun Stagnation?
Die Celldex Therapeutics Aktie verzeichnete am 12. März 2025 eine deutliche Erholung mit einem Plus von 4,81 Prozent auf 20,50 USD im Vergleich zum Vortag. Diese positive Entwicklung steht im
Pfizer Stock: Shares Drop Despite Cancer Drug Progress
Pfizer's stock fell 1.7% to $26.20 in Tuesday afternoon trading on the New York Stock Exchange, despite the company announcing promising results from a key clinical trial. The decline came amid
Bristol-Myers Squibb Stock: $286M Acquisition Targets Cancer Therapy
Bristol-Myers Squibb has announced a definitive agreement to acquire biotechnology company 2seventy bio for $5.00 per share in an all-cash transaction. The deal values 2seventy bio at approximately
Cerus Stock: Insider Sales Amid Positive Business Growth
Cerus Corporation's leadership team has recently executed several stock sales, drawing investor attention as the transactions occurred while shares traded near their 52-week low. The company's CEO
Align Stock: AI Diagnostic Software Launches Amid Financial Challenges
Align Technology, a digital dentistry leader valued at $12.1 billion, has announced the European Union and UK launch of its AI-powered "Align X-ray Insights" diagnostic software. The cloud-based
CryoLife Stock: Executives Sell Shares As Cybersecurity Issue Impacts Results
The leadership team at CryoLife, a medical technology company with a market capitalization approaching $1 billion, has recently executed multiple stock transactions. Chief Financial Officer Lance
Johnson & Johnson Stock: New Cancer and Colitis Treatments Show Promise
Johnson & Johnson's stock could receive significant momentum following positive developments in multiple therapeutic areas. The company recently secured approval from Health Canada for a combination
If You Could Only Hold 3 Investments for Life, Consider These
Warren Buffett, who is known to own “forever stocks,” has famously quipped that if you aren’t willing to own a stock for 10 years, you shouldn’t own it for even 10 minutes.
This idea prompts a
BioNTech veröffentlicht Ergebnisse für das vierte Quartal und das Geschäftsjahr 2024 sowie Informationen zur Geschäftsentwicklung
- Onkologie-Pipeline weiterentwickelt mit mehr als 20 aktiven klinischen Phase-2- und Phase-3-Studien mit strategischem Fokus auf zwei tumorübergreifende (Pan-Tumor-)Programme:
Eli Lilly Stock: Skin Drug Shows Strong Long-term Results
Eli Lilly has reported significant progress with its medication Ebglyss for moderate to severe atopic dermatitis. At the American Academy of Dermatology annual meeting in Orlando, the company
Cytokinetics Stock: Executives Sell Shares Despite Growth Outlook
Cytokinetics Inc. has recently seen multiple executives selling portions of their stock holdings, all reportedly to cover tax obligations related to Restricted Stock Unit transfers. CEO Robert Blum
Halozyme Therapeutics Aktie: Optimismus im Aufbruch!
Die Halozyme Therapeutics Aktie verzeichnete am 8. März 2025 einen weiteren Kursanstieg von 1,38 Prozent und notiert aktuell bei 60,98 USD. Der Biotechnologiewert setzt damit seinen positiven Trend
Blueprint Medicines Stock: Executives Sell Shares Amid Growth
Blueprint Medicines, a biopharmaceutical company headquartered in Cambridge, Massachusetts, recently reported several significant stock transactions by its leadership team. Multiple executives sold
Pfizer Stock: Nearing 52-Week Lows Amid Challenges
Pfizer's stock currently faces a challenging market position, trading precariously close to its 52-week lows. The shares recently showed minimal recovery, rising just 0.2 percent to $25.99 in New